Esperion Therapeutics (NASDAQ:ESPR) Earns “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR) in a research note released on Thursday morning,Benzinga reports. HC Wainwright currently has a $16.00 price target on the biopharmaceutical company’s stock.

Several other equities analysts also recently issued reports on ESPR. The Goldman Sachs Group initiated coverage on shares of Esperion Therapeutics in a report on Wednesday, December 18th. They set a “neutral” rating and a $4.00 price target for the company. StockNews.com lowered shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Cantor Fitzgerald began coverage on shares of Esperion Therapeutics in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $8.00 price target on the stock. Finally, Needham & Company LLC reiterated a “buy” rating and set a $6.00 price objective on shares of Esperion Therapeutics in a research report on Friday, December 13th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, Esperion Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $7.25.

Esperion Therapeutics Stock Down 5.5 %

ESPR opened at $2.08 on Thursday. The company’s 50-day moving average price is $2.46 and its 200 day moving average price is $2.18. Esperion Therapeutics has a fifty-two week low of $1.58 and a fifty-two week high of $3.94. The firm has a market cap of $409.84 million, a price-to-earnings ratio of -3.25 and a beta of 1.03.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). The firm had revenue of $51.63 million during the quarter, compared to analyst estimates of $55.44 million. During the same quarter last year, the firm earned ($0.37) EPS. Research analysts anticipate that Esperion Therapeutics will post -0.28 earnings per share for the current year.

Institutional Trading of Esperion Therapeutics

Institutional investors have recently made changes to their positions in the stock. Traphagen Investment Advisors LLC bought a new stake in Esperion Therapeutics during the third quarter worth approximately $27,000. Xponance Inc. acquired a new position in shares of Esperion Therapeutics during the 2nd quarter valued at $28,000. Versor Investments LP acquired a new position in shares of Esperion Therapeutics during the 3rd quarter valued at $44,000. American Century Companies Inc. bought a new stake in shares of Esperion Therapeutics in the 2nd quarter worth $50,000. Finally, SJS Investment Consulting Inc. acquired a new stake in shares of Esperion Therapeutics in the fourth quarter valued at $55,000. 47.39% of the stock is owned by institutional investors and hedge funds.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.